TC
TCRT icon

Truvestments Capital’s Alaunos Therapeutics TCRT Stock Holding History

Truvestments Capital’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$2 – 1099
2025
Q3 		$2 Hold
1
– – ﹤0.01% 1057
2025
Q2 		$5 Hold
1
– – ﹤0.01% 981
2025
Q1 		$1 Buy
+1
New +$2 ﹤0.01% 1029
2024
Q2 		– Hold
0
– -$2 – 635
2024
Q1 		– Hold
0
– – – 726
2023
Q4 		– Hold
0
– – – 795
2023
Q3 		– Hold
0
– – – 682
2023
Q2 		– Hold
0
– – – 690
2023
Q1 		– Hold
0
– – – 666
2022
Q4 		– Hold
0
– – – 919

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Truvestments Capital's TCRT Position: Q4 2025 in Review

Truvestments Capital sold out of Alaunos Therapeutics (TCRT) in Q4 2025, closing a stake of 1 share — an estimated $2 sold.

Truvestments Capital first reported a position in TCRT in Q1 2025 and held it in 3 quarters. The position peaked at $5 in Q2 2025. 27 funds tracked by Wall St. Rank hold TCRT as of Q4 2025.

  • Truvestments Capital reported no remaining Alaunos Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Truvestments Capital sold 1 Alaunos Therapeutics share in Q4 2025, an estimated $2.
  • Truvestments Capital first reported a position in Alaunos Therapeutics in Q1 2025 and held it in 3 quarters.
  • Truvestments Capital's Alaunos Therapeutics position peaked at $5 in Q2 2025.
  • 27 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2025.

Based on Truvestments Capital's 13F filing for Q4 2025, filed 13 Feb 2026.